Cite
MLA Citation
T. Matsutani et al.. “FRI0206 Abatacept (CTLA4-IG) suppresses T cell activation and reduces TH17 cells as well as plasma IL-6 in patients with rheumatoid arthritis.” Annals of the rheumatic diseases, vol. 71, n.d., p. 383. http://access.bl.uk/ark:/81055/vdc_100136586665.0x00005d